30 . 11 .2023
Press release
Results from Galderma’s phase IIIb trials demonstrate rapid and long-lasting effect of RelabotulinumtoxinA on crow’s feet and frown lines
21 . 11 .2023
Press release
Galderma reports record net sales of over 3 B USD for the first nine months of 2023 with strong growth momentum across all product categories
26 . 10 .2023
Press release
Galderma phase III data published in The New England Journal of Medicine: full Olympia 2 trial results demonstrate nemolizumab’s rapid onset of action in patients with prurigo nodularis
13 . 10 .2023
Press release
Galderma unveils bold ambition in neuromodulation at Liquid Live event
11 . 10 .2023
Press release
Galderma @ EADV 2023: phase III trials demonstrate nemolizumab’s efficacy and rapid onset of action in atopic dermatitis and prurigo nodularis
04 . 10 .2023
Press release
EADV 2023: Galderma to present new data showcasing its continued leadership in dermatology
03 . 10 .2023
News story
“A product for any type of skin”: celebrating Cetaphil’s range and reliability